title: Tackling non-muscle invasive bladder cancer in the clinic.
abstract: Non-muscle invasive bladder cancer (NMIBC) is a common disease process with a high propensity for recurrence and risk of progression to muscle-invasive or systemic disease. Optimal management of NMIBC depends on appropriate resection and staging, risk-based use of intravesical therapy and tailored surveillance. Current challenges include compliance with guideline recommendations and cancers which are refractory to standard therapies. Areas covered: This review summarizes the conventional management of NMIBC - which relies on strict cystoscopic surveillance and intravesical therapies with chemotherapy and/or immunotherapy in the form of bacillus Calmette-Guerin (BCG). As many patients will be resistant to conventional treatment, investigational therapies and novel prognostic models will also be discussed. Expert commentary: For decades, the management of NMIBC has been predicated on intravesical therapies, most often through the instillation of BCG which has proven clinical efficacy over transurethral resection alone. Despite this, many patients will recur or progress after BCG therapy. While radical cystectomy remains the standard for such patients, suitable alternatives are being actively investigated. An increased interest in immunotherapy for malignancy has reinvigorated this field and on-going advances in disease prognostication are likely to improve upon the existing treatment paradigms for NMIBC.
authors.affiliation: a Department of Urology , University of Texas Southwestern Medical Center , Dallas , TX , USA.
authors.forename: Solomon L
authors.initials: SL
authors.lastname: Woldu
authors.affiliation: a Department of Urology , University of Texas Southwestern Medical Center , Dallas , TX , USA.|b Department of Urology, Istanbul Faculty of Medicine , Istanbul University , Istanbul , Turkey.
authors.forename: Öner
authors.initials: Ö
authors.lastname: Şanli
authors.affiliation: a Department of Urology , University of Texas Southwestern Medical Center , Dallas , TX , USA.
authors.forename: Yair
authors.initials: Y
authors.lastname: Lotan
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D001500:BCG Vaccine / Q000008:administration & dosage; D003131:Combined Modality Therapy; D015653:Cystectomy / Q000379:methods; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D017410:Practice Guidelines as Topic; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*
chemical_list: D000970:Antineoplastic Agents; D001500:BCG Vaccine
keywords: BCG; Non-muscle invasive bladder cancer; chemothermotherapy; electromotive drug administration; intravesical therapy; novel